The biotech's sleep drug Hetlioz gained an expanded approval. One of the hallmarks of SMS is that patients have a hard time sleeping during the night. It's a fairly rare disease -- Vanda estimates ...

News of an update from the U.S. Food and Drug Administration (FDA) pushed Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares sharply higher early Wednesday. Essentially, the agency approved Vanda’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The D.C. biotech grew revenue for its products — in a ...

Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...

Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is making ...

WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, ...

It's the first approved treatment for Smith-Magenis Syndrome. Vanda’s latest study failed. But revenue grew in 2019. © 2025 American City Business Journals. All ...

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.09 per share a year ago. These ...

Yesterday, retail traders had the weakest buying day since Biden's election rally, Vanda found. The longer this year's market slump continues, the more retail traders will tire, the analysts said.

Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC ...